LOCAL PROVIDER DIRECTORY
Find a dentist
Search by name or specialty, then choose a city and region or enter a ZIP / postal code.
Choose a location to keep your results local.
Local Health Alerts
RSV vaccine in pregnancy: what parents of newborns should know
There are two main ways to help protect babies from severe RSV: maternal vaccination during a narrow pregnancy window, or an infant RSV monoclonal antibody after birth. CDC says the right option depends on timing, eligibility, and whether a mother already received RSV…
FDA pushes better pregnancy safety data for medicines
The FDA has issued new guidance aimed at improving how pregnancy safety data are collected for drugs and biologics. For patients, the practical takeaway is not that treatment rules changed today, but that the evidence base for medicine use in pregnancy may become…
CDC’s March 2026 kidney disease update supports earlier screening
New CDC estimates show chronic kidney disease remains common in the U.S. and often goes unnoticed. Adults with diabetes, high blood pressure, heart disease, or a family history of kidney disease may have the most to gain from earlier screening and follow-up in…
Breast Screening Debate Heats Up as U.S. Guidance Stands
Breast cancer screening is back in the news because policy leaders and researchers are revisiting how mammograms should be recommended and covered. For most average-risk U.S. women, the practical advice has not changed: keep following current screening guidance and confirm your schedule with…
FDA Pushes Faster Trial Reporting as NIH Updates Its Rules
The FDA is pressing sponsors and researchers to report clinical trial results on time, saying missing data can distort what doctors and patients think they know. A new FDA push and an NIH policy update are raising the stakes for transparency as the…
FDA expands Enhertu use in early HER2-positive breast cancer
The FDA’s May 15 approval adds two early-stage breast cancer uses for Enhertu, also known as fam-trastuzumab deruxtecan-nxki. The update matters for some adults with HER2-positive disease, but it does not change screening guidance or replace a discussion about surgery, chemotherapy, and other…
New trial finds patient navigation may help after a positive FIT
A new randomized clinical trial suggests centralized patient navigation can help people get a follow-up colonoscopy sooner after a positive FIT stool test. The finding matters because a FIT is a screening step, not the endpoint: an abnormal result still needs diagnostic follow-up.
Long COVID in 2026: Fatigue, Prevention, and Higher-Risk Groups
New CDC guidance and fresh research reinforce the same core message: long COVID can follow even a mild infection, normal tests do not rule it out, and the best proven way to lower risk is still reducing the chances of severe COVID-19. Early…
FDA’s rare-disease approval push could widen access for ultra-rare therapies
The FDA says it wants to make room for individualized treatments in ultra-rare diseases without lowering the bar for evidence. A new draft framework, plus several 2026 approvals, shows how regulators are trying to balance flexibility with proof that a therapy targets the…
FDA’s New Pregnancy-Safety Guidance Could Improve Medicine Data
The FDA has finalized new guidance on collecting pregnancy-safety data after a drug or biologic is approved. The change will not rewrite labels overnight, but it could strengthen the evidence doctors and patients rely on when deciding whether medicine is needed during pregnancy.
Earlier LDL lowering for primary prevention: what new evidence changes
New 2026 research adds momentum to earlier LDL lowering for people without prior heart attack or stroke. But the basics have not changed: healthy habits, blood pressure control, cholesterol screening, and statins remain the mainstay for most primary prevention decisions.
Should breast screening depend on risk instead of age?
A large randomized trial suggests breast cancer screening can be tailored by risk without missing more advanced cancers compared with standard screening. But U.S. guidance has not broadly shifted yet, and experts still see important limits in the evidence.
